Trading Signals: BNTX Stock Price Prediction and Forecast (Thu. Oct. 10, 2019 - Fri. Dec. 22, 2023)(BioNTech SE )
| BNTX latest price $161.2900 (-5.31%) ($161.2900 - $161.2900) on Fri. Mar. 25, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.35% (three month average) | RSI | 72 | Latest Price | $161.2900(-5.31%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | BNTX declines -1.6% a day on average for past five trading days. | Weekly Trend | BNTX advances 11.5% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support BNTX advance at 0% a week (0% probability) ARKK(43%) IBB(42%) XBI(39%) BOTZ(37%) ONLN(35%) | Factors Impacting BNTX price | BNTX will decline at least -2.675% in a week (0% probabilities). VIXM(-23%) UUP(-13%) TBT(-9%) VXX(-1%) USO(0%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.675% (StdDev 5.35%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $168.56(-4.31%) | 10 Day Moving Average | $164.7(-2.07%) | 20 Day Moving Average | $152.4(5.83%) | To recent high | -37.3% | To recent low | 28% | Market Cap | $37.528b | | | | BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.July 1, 2020. BioNTech and Pfizer have released the most detailed information so far among the vaccine candidates being tested in the U.S., 24 participants in the Phase 1/2 clinical trial who received two doses of the lower-dose vacc.ines developed neutralizing antibodies. |